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• Extension of mono to diaryl hydroxylamines illuminates activities as potent pan and dual 
inhibitors of IDO1, IDO2 and TDO.  
• There is a paucity of previous reports of dual and pan inhibitors for these enzymes, which 
regulate the kynurenine pathway. 
• Aryl halide substitution generated the most potent derivatives studied. 
ABSTRACT  Tryptophan (Trp) catabolizing enzymes play an important and complex role in the 
development of cancer. Significant evidence implicates them in a range of inflammatory and 
immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) 
have been reported and analyzed in the clinic, fewer inhibitors have been described for 
  
tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have 
been implicated more recently in cancer, inflammation and immune control. Consequently the 
development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a 
therapeutically important area of research. This is the first report to describe the development of 
dual and pan inhibitors of IDO1, TDO and IDO2.   
1. Introduction 
In mammals and other vertebrates, three enzymes, IDO1, IDO2 and TDO, catalyze the 
rate-limiting first step of tryptophan catabolism down the kynurenine pathway which accounts 
for ≥95% of tryptophan catabolism1, 2. Whereas TDO is a predominantly hepatic enzyme 
functioning to maintain tryptophan homeostasis, IDO1 is induced by inflammation, particularly 
by IFN, and can be found in lymphoid tissues and organs, along mucosal surfaces, and in the 
placenta and epididymis3. IDO2 has been less thoroughly investigated than the other two 
enzymes, but the available data indicate it has a more restricted expression than IDO13. In cancer 
patients, IDO1 expression has been observed at varying levels and frequencies in most tumor 
types while TDO is strongly expressed in hepatocarcinoma, but also weakly in many other tumor 
types3Extensive preclinical evidence indicates that IDO1 inhibitors can relieve T cell suppression 
and enhance cancer therapeutic responses4, 5, including when combined with cytotoxic 
chemotherapy, radiotherapy or immune checkpoint therapy6-9. Nevertheless, the failure of the 
IDO1-selective inhibitor epaccadostat to provide a benefit in combination with the immune 
checkpoint agent pembrolizumab in a recent phase III clinical trial10 in melanoma patients 
highlights the continuing challenges to exploit the role IDO1 has in regulating the immune 
system.   
  
While this trial has raised many questions11, attendant with its failure has been the 
growing recognition of the complex role and importance of the related dioxygenases, TDO and 
IDO24, 5, which, like IDO1, also exert root functions in cancer inflammatory programming. It has 
become clear that IDO1 drives both neovascularization along with immunosuppression in 
tumors.12, 13 TDO promotes immunosuppression, but also other processes that promote metastatic 
progression3, 14-17. IDO2 drives inflammation in autoimmune and cancer settings including 
pancreas cancer18-20. Combo or pan IDO1/TDO/IDO2 inhibitors will potentially offer metabolic 
adjuvants to illuminate key questions concerning the peculiar nature of chronic inflammatory 
states that sustain cancer21.  As metabolic adjuvants, IDO1-selective inhibitors do not plumb the 
full potential of blunting Trp catabolism. Emerging evidence indicates that TDO and IDO2 are 
jointly activated with IDO1 in many tumors3, 14-17, 22, arguing for independent as well as 
overlapping functions. Whereas IDO1 modulates T-cell inflamed states, IDO2 influences B-cell 
inflamed states critical for autoimmunity20 as well as certain cancers like pancreatic cancer23, 24. 
IDO2 targeting may pose an additional benefit in mitigating autoimmune side-effects of immune 
checkpoint therapy based on evidence of a role in autoimmune inflammation20, 25. Lastly, 
resistance to IDO1 blockade in preclinical models is associated with upregulated Trp catabolism 
down the kynurenine pathway by TDO or IDO212. In the wake of these discoveries, the next 
logical step would be the development of dual or broad spectrum inhibitors of tryptophan 
catabolism to target IDO1, IDO2 and TDO.   
Although a large number of IDO1 inhibitors have been communicated26, 27, there are 
significantly fewer TDO22, 28-32 and IDO2 inhibitors33-35 described in the literature. To the best of 
our knowledge, there is only one report of dual inhibition in the literature31, although a collection 
of  patents have appeared36-39.  Our recent report of monoaryl hydroxylamine activity as an 
  
impressive, structurally simple IDO1 inhibitor40 prompted us to explore this structural class of 
compounds further for combinatorial activity against IDO/TDO enzymes. Cognizant of the 
potential therapeutic benefits that might accrue from joint inhibition of IDO2 and TDO, we 
therefore screened more broadly for the effects of diaryl hydroxylamines on IDO2 and TDO as 
well as IDO1, to identify pan or selective inhibitors.  
Based on literature defining two major pockets termed A and B in the active site of 
IDO126, 41-43. The expansion of our previously reported monoaryl hydroxylamines to diaryl 
derivatives was conceived initially as an effort to exploit both pockets in IDO1 to achieve more 
potent and selective inhibition. In addition, IDO1’s substrate profile has always suggested greater 
promiscuity relative to TDO44, 45 and the reported flexibility of the enzyme41 likely contributes to 
the ability of IDO1 to accommodate a range of structures. We were cognizant of these challenges 
and opportunities as we explored a new structural derivative of the monoaryl hydroxylamines. 
Herein we report our results with regards to these studies.  
2. Results and Discussion 
2.1 Synthesis of diaryl inhibitors.  
The synthesis of the diaryl inhibitors followed the pattern of the previously reported 
monoaryl hydroxylamines40 in using the Mitsunobu reaction of an alcohol with N-
hydroxyphthalimide to create the critical hydroxylamine functional group. The alcohol 
precursors of the Mitsunobu reaction were usually synthesized by adding phenyllithium or 
phenyl Grignard to the appropriate aldehyde (Scheme 1). Details for the synthesis of all alcohol 
precursors to the Mitsunobu reaction are shown in the Supplementary Data appendix. The 
  
Mitsunobu sequence shown in Scheme 2 illustrates the transformation of the alcohol substrates 
to O-alkylhydroxylamines.  
Scheme 1. Synthesis of Diaryl Alcohols with One Ring Substituted 
 
Scheme 2.Mitsunobu Reaction to Convert Alcohols to O-Alkyl Hydroxylamines 
 
2.2 Enzyme inhibition data analysis.  
Analysis of the diaryl compounds with isolated enzyme assays for IDO1, IDO2 and TDO 
activity allowed a preliminary ranking of the derivatives (Table 1). These results illustrated an 
array of activity and selectivity in this class of dioxygenase inhibitors. In all cases, compounds 
were tested as racemic mixtures, so it is possible that one enantiomer is the preferred and more 
potent stereoisomer. IDO1, which is the primary focus of most therapeutic work, was most 
potently inhibited by compounds with bromo and chloro substituents on the aromatic rings 
(compounds 1-7) with a potency in the range of 1-4 M. This was also consistent with the results 
from our studies with the monoaryl hydroxylamines40. Methoxy or hydroxy substituted 
derivatives (20, 23, 25) were noticeably less potent (23 M, 85% inhibition and 18% inhibition, 
  
respectively). The preference for bromo and chloro substitution on IDO1 inhibitors has also been 
found with the most potent compounds that have entered the clinic4. 
In addition to the potency enhancing effects of halogenated derivatives towards IDO1 
inhibition, we found two modifications that often led to IDO1 selective inhibitors: 2-fluoro 
substitution of one aryl ring (10, 12, 13, 16) and diaryl derivatives with a longer chain of atoms 
between the two aryl rings (5, 11, 17). In the ortho-fluoro substitution cases, the two most potent 
examples also have a trifluoromethyl group on the same ring and therefore the highly electron 
deficient aryl ring may be critical for IDO1 selectivity. With respect to the diaryls with greater 
distance between the two aryl rings, their selectivity is likely the result of the extended second 
aryl group better occupying the B pocket of IDO1. Inhibitors that occupy both the A and B 
pockets of IDO1 often have greater potency42, 43, although, to the best of our knowledge, our 
discovery is the first to illustrate selectivity from an extended binding inhibitor. This could be 
critical to the development of more selective inhibitors of the dioxygenase family.  
New pan, dual and selective dioxygenase inhibitors were also identified (Fig. 1). For 
example, compound 3 with the 3,4-dichloro aryl ring substitution, was a pan inhibitor 
(IDO1/IDO2/TDO potency: 2, 32, 4 M, respectively). Several of the chlorinated and fluorinated 
derivatives demonstrated dual IDO1/TDO inhibition, including 4 (4,4’-dichloro), 6 (2,4-
dichloro), 8 (4-chloro), 9 (3-fluoro), 14 (2,3-dichloro), and 15 (4,4’-difluoro). All six had IDO1 
and TDO IC50 values in the single digit micromolar range. One dual IDO1/IDO2 inhibitor was 
identified in the 2-chloro substituted diaryl derivative, compound 19, which had IC50 values of 
18 and 25 M for IDO1 and IDO2, respectively. There was one diaryl compound (26) tested that 
was a selective TDO inhibitor (12 M).  Twelve of the other compounds were IDO1 selective: 1, 
2, 5, 7, 10-13, 16-18, and 20. As noted earlier, seven of these derivatives fit into one of two 
  
categories: (1) 2-fluoro substitution (10, 12, 13, 16) or (2) extended distance between the two 
aromatic rings (5, 11, 17). Four of the IDO1 selective inhibitors had 3,5-dihalo (2 and 7) or 2-
position substitution (18 and 20). The most potent compound, 1, fit none of these patterns as it 
had a 3-bromo substitution, thereby demonstrating the empirical nature of much of this analysis.  
 




Structurea IDO1 (M or % 
inhibition)b 
IDO2 (M or % 
inhibition)b 
TDO (M or % 
inhibition)b 
1 3-bromo 1 M 77.6% 92.6% 
2 3,5-dichloro 2 M  69.8% 83.4% 
3 3,4-dichloro 2 M 32 M 4 M 
4 4,4’-dichloro 3 M   69.3% 2 M 
5 
  
3 M  84.3% 75.5% 
6 2,4-dichloro 4 M 73% 6 M 




8 4-chloro 5 M 74.3% 5 M 
9 3-fluoro 5 M 82% 6 M 
10 2-fluoro-3-trifluoromethyl 6 M 81.1% 93.2% 
11 
 
7 M  78.1% 93.1% 
12 2,4-difluoro 7 M 46% 90.3% 
13 2-fluoro-5-trifluoromethyl 8 M 73.8% 73.4% 




15 4,4’-difluoro 9 M 73.6% 9 M 
16 2-fluoro 12 M 77.8% 87.2% 
17 
 
16 M 76.0% 89.9% 
18 2-bromo 17 M 81.0% 90.4% 
19 2-chloro 18 M 25 M 89.8% 
20 2-methoxy 23 M 80.0% 80.3% 
21 
 
83% 76.5% 93.3% 
22 
 
76% 88.6% 43.6% 
23 2-methoxy-4-methyl-4’chloro 85% 73.8% 66%  
24 3,5-bis(trifuoromethyl) 56% 53.3% 50.8% 
25 4-hydroxy 18.3% 72.3% 48.7% 
26 3-trifluoromethyl 18% 36.1% 12 M 
a In all structures, n=0 unless otherwise shown.  
bThe inhibition activity of each compound as listed was first tested with 100 M inhibitor (except 24 and 
25, which were tested with 200 M inhibitor), IC50 values were then determined for those exhibiting >95% 
inhibition activity.  
 





2.3 Cell-based data analysis.  
The first point that was noticeable in the cell-based IC50 data (Table 2) was that almost all 
inhibitors demonstrated more potent inhibition than in the isolated enzyme assay. This is quite 
common with IDO1 screens46, 47 and seems reasonable to expect for the similarly challenging 
isolated enzyme assays for TDO and IDO2. In particular, the IDO1 enzyme assay uses a surrogate 
reduction system (typically methylene blue and ascorbic acid) which is not the native reduction 
operation, to maintain the IDO1 in its catalytically active ferrous state; for although there is no 
redox cycling in the catalytic reaction, IDO1 is quite prone to oxidation to the ferric heme in the 
presence of oxygen. Also, as with the isolated enzyme assays, all compounds were tested as 
racemic mixtures.  
The cell-based and isolated enzyme screens generally demonstrated similar relative 
potency for IDO1, IDO2 and TDO in most cases, although some differences in selectivity profiles 
were observed. For example, the same bromo and dichloro substituted derivatives (1-4) that were 
potent IDO1 inhibitors in the isolated enzyme assay were also potent IDO1 inhibitors in the cell-
  
based assays (0.6-2 M). However, the cell-based data for these compounds exhibited more 
significant potency with IDO2 and TDO as well. Indeed, most of the diaryl compounds 
demonstrated pan inhibition with high nanomolar or low micromolar inhibition of all three 
tryptophan catabolizing enzymes (Figure 2) . In all these cases, the potency for IDO1 was the 
strongest, albeit in some examples only marginally so or within experimental error.  For 
comparison and as proof of the significant pan inhibitor potency of the diaryl hydroxylamines, two 
clinical IDO1 inhibitor candidates, epacadostat (INCB24360) and PF-068400003, were tested and 
are included in Table 2 and the Venn Diagram Figure 2. Although INCB24360 shows pan 
inhibition at roughly the same level as many of the more IDO1 selective diaryl inhibitors, the 
structural simplicity of the diaryl hydroxylamine inhibitors and their ease of synthesis (3 steps 
versus 14 steps for epacadostat) makes them an important discovery and an exciting new lead 
compound series. 
 
As with the enzyme assays, the halogenated derivatives (fluoro, chloro and bromo) were 
the most potent and, within these examples, the dihalogenated versions (2-4, 6, 7, 12, 14, 15) 
demonstrated stronger pan inhibition than the monohalogenated analogs (5, 8, 11, 16, 18, 19), 
which had at least one inhibition constant above 20 M. The meta monofluorinated 9 demonstrated 
IDO1 selective inhibition, along with three ortho monosubstituted derivatives 18-20, which had 
roughly five- to ten-fold greater potency with IDO1 (~1 M) than either IDO2 (~10 M) or TDO 
(>20 M). The power of ring halogenation was also witnessed in our previous report40 on monoaryl 
O-alkylhydoxylamine derivatives as IDO1 inhibitors. 
As with the isolated enzyme assay, the extended binding inhibitor 5 with the greater 
distance between the two aryl rings demonstrated more than 20-fold selectivity for IDO1 over 
  
IDO2 and TDO. However, the other extended binding inhibitors, 11 and 17, were less potent and 
less selective, illustrating that compound 5 has the better distance between the two aryl rings to 
generate selective and maximum IDO1 inhibition. Interestingly, there were two compounds, 16 
and 21, which showed dual IDO1/TDO inhibitor activity with roughly 10-fold greater potency for 
IDO1 and TDO (~1-5 M) over IDO2 (~30-50 M). Notably, the loss of the second aryl ring, as 
in compound 22, resulted in significant attenuation in overall inhibition activity and for TDO in 
particular. This example serves as an important illustration of the requisite diaryl character in these 
inhibitors. Surprisingly, the four least potent compounds in the isolated enzyme assay (23-26) 
showed single micromolar potency towards IDO1 in the cell-based assay and retained low 
micromolar inhibition of IDO2 and TDO. Again, this is likely attributed to differences in the 
isolated enzyme assay procedure versus the cell-based assay.  
 









0.07 18.9 25.2 
PF-06840003 
 
0.21 327 378 
1 3-bromo 0.590 11.8 7.15 
2 3,5-dichloro 0.870 8.66 5.70 
  
3 3,4-dichloro 1.91 19.5 8.11 
4 4,4’-dichloro 1.09 12.5 4.53 
5 
 
1.43 36.1 123 
6 2,4-dichloro 1.99 7.68 4.82 
7 3,5-difluoro 0.357 8.75 3.48 
8 4-chloro 7.15 27.8 23.7 
9 3-fluoro 0.939 9.99 6.21 
10 2-fluoro-3-trifluoromethyl 0.933 16.8 5.62 
11 
 
6.74 20.5 58.7 
12 2,4-difluoro 1.21 18.9 6.37 
13 2-fluoro-5-trifluoromethyl 1.09 8.94 9.02 
14 2,3-dichloro 1.87 8.95 4.54 
15 4,4’-difluoro 1.68 12.1 5.15 
16 2-fluoro 1.26 30.5 3.92 
17 
 
14.7 19.3 49.7 
18 2-bromo 1.46 12.3 22.5 
19 2-chloro 2.48 10.7 21.8 
20 2-methoxy 1.11 16.5 48.8 
21 
 
3.36 49.9 4.41 
22 
 
21.0 40.2 2770 
23 2-methoxy-4-methyl-4’chloro 1.76 8.77 19.1 
24 3,5-bis(trifuoromethyl) 3.35 14.5 77.4 
25 4-hydroxy 2.89 12.6 29.8 
26 3-trifluoromethyl 1.73 24.7 13.6 
a In all structures, n=0 unless otherwise shown.  
  
bThe IDO1 assay used HeLa cells, the IDO2 assay used mouse Trex cells and the TDO assay used Trex 
cells. Data is from a single data point except for the most potent compounds, which were done in triplicate 
and the results averaged. 
 
 
Figure 2. Venn diagram of selectivities seen with diaryl hydroxylamines in cell-based assay. 
 
 Compound associated cytotoxicity could be a possible complicating factor for 
interpreting the cell-based enzyme inhibition data and a potential concern with regard to safety 
and tolerability. Therefore, a viability screen with HeLa cells was undertaken which 
demonstrated roughly ≥80% viability up to 100 M for all compounds except for 1, 12 and 24 
(See Supplementary Data appendix, Figure S3). For these three compounds, the cell viability 
dropped to approximately 60% around 100 M. The overall lack of cytotoxicity apparent at the 
effective inhibitory dose range for these compounds suggests that general cytotoxicity is not 
  
likely to be an issue for advancing the diaryl hydroxylamine series. It was clear that the diaryl 
hydroxylamines, like the monoaryl hydroxylamines, have little to suggest that they would be 
problematic. Assessment of impact of human serum protein binding indicated a substantial 
reduction in inhibitory activity for one of the compounds, 6, while the inhibitory activity of 2 
was relatively unaffected (see Supplementary Data appendix, Figure S4). This analysis indicates 
that it should be possible to develop diaryl hydroxylamines inhibitors that are not unduly 
compromised by serum protein binding. 
3. Conclusions 
Several important discoveries were made in the studies reported here. First, diaryl 
hydroxylamines demonstrated strong potency in isolated enzyme assays and were even stronger 
in cell-based assays. This reaffirms a common pattern for IDO1 inhibition studies and alerts 
researchers in the field that isolated enzyme studies should be interpreted with caution. This is 
understandable because the isolated enzyme assay for these Trp catabolizing enzymes is not an 
accurate replication of the actual cell environment. Second, the value of halogenation (fluoro, 
chloro and bromo) to potency in all three enzymes is a critical recognition, echoing the most 
potent IDO1 inhibitors that have entered the clinic. Third, as seen with 5, extended binding 
inhibitors do offer selectivity for IDO1 over the two other dioxygenase enzyme targets. Most 
notably, this study illustrates a rare example of potent pan and IDO1/TDO selective inhibitors. 
Although IDO1 inhibitors have been developed and reported for over a decade26, the 
development of pan or variably selective inhibitors is still in its infancy. Indeed, given the recent 
failure of the IDO1-selective inhibitor epacadostat in the ECHO-301 Phase 3 trial in melanoma, 
it seems likely that dual or pan inhibitors may be important to the development of effective 
therapeutic inhibitors of tryptophan catabolism11. The illustration in this report that these 
  
relatively simple inhibitors have significant potency and unique selectivity is an important 
development in the field that should benefit other researchers. Future studies will seek to further 
advance these understandings in the creation of more therapeutically relevant structures.  
 
4. Experimental Section 
General Synthetic Chemistry Experimental Parameters 
All reactants and reagents were commercially available and were used without further 
puriﬁcation unless otherwise indicated. Anhydrous CH2Cl2 was obtained by distillation from 
calcium hydride under nitrogen.  Anhydrous THF was freshly distilled from Na and benzophenone. 
All reactions were carried out under an inert atmosphere of argon or nitrogen unless otherwise 
indicated. Concentrated refers to the removal of solvent with a rotary evaporator at normal water 
aspirator pressure followed by further evacuation with a direct-drive rotary vane vacuum pump. 
Thin layer chromatography was performed using silica gel 60 Å precoated glass or aluminum 
backed plates (0.25 mm thickness) with ﬂuorescent indicator, which were cut. Developed TLC 
plates were visualized with UV light (254 nm), iodine, or ninhydrin. Flash column chromatography 
was conducted with the indicated solvent system using normal phase silica gel 60 Å, 230-400 
mesh. Yields refer to chromatographically and spectroscopically pure (>95%) compounds except 
as otherwise indicated. Melting points were determined using an open capillary and are 
uncorrected. 1H NMR spectra were recorded at 400 MHz. Chemical shifts are reported in δ values 
(ppm) relative to an internal reference (0.05% v/v) of tetramethylsilane (TMS) for 1H NMR. Peak 
splitting patterns in the 1H NMR are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; 
m, multiplet; br,broad. 13C NMR experiments were conducted with the attached proton test (APT) 
pulse sequence. 13C multiplicities are reported as δu (up) for methyl and methine, and δd (down) 
  
for methylene and quaternary carbons. HPLC was conducted on an Agilent 1100 with an Ascentis 
Express C-18 column (100 x 4.6 mm, 2.7 m) and a mobile phase of 80:20 MeCN:H2O. GC 
analyses were performed on the free hydroxylamine with an EI-MS detector fitted with a 30 m x 
0.25 mm column filled with cross-linked 5% PH ME siloxane (0.25 µm film thickness); gas 
pressure 7.63 psi He. Analysis of samples involved heating from 70 to 250°C (10°C/min) and 
finally holding at 250°C for 7 min. All compounds were found to be >95% purity by elemental 
analysis or GC as indicated. 
General Synthesis of O-Alkyl Hydroxylamines.  
To a solution of alcohol (1 mmol) in freshly distilled THF (5 ml) was added triphenylphosphine 
(1.1 mmol) and N-hydroxylphthalimide (1.1 mmol). After the solution was cooled to 0oC 
diisopropylazodicarboxylate (1.1 mmol) was added dropwise. The solution was allowed to warm 
to room temperature over 3 hours. Reaction progress was monitored by TLC (1:1 heptanes:ethyl 
acetate).  Hydrazine monohydrate (1.1 mmol) was then added and the solution was allowed to stir 
for 30 min. Water was added to dissolve the white precipitate. The aqueous layer was then 
extracted with ethyl acetate 3 times, washed with brine, and dried over Na2SO4. Removal of the 
solvent under reduced pressure afforded a yellow oil that was purified by flash chromatography 
(1:1 heptanes/ethyl acetate with 0.1% triethylamine).  
HCl salt formation:  The O-alkyl hydroxylamine was dissolved in a minimal amount of diethyl 
ether. HCl in anhydrous diethyl ether (1.0 M, 1 eq) was added slowly. The white precipitate was 
filtered and washed with diethyl ether and dried under high vacuum.  
O-(3-Bromo-α-phenylbenzyl)hydroxylamine hydrochloride (1). Synthesized from 3-bromo-α-
phenyl-benzenemethanol according to the general procedure to afford 1 as white crystals in 66% 
yield. Mp=159-162oC. 1H NMR (CD3OD) δ 7.57-7.60 (m, 2H, ArH), 7.33-7.52 (m, 7H, ArH), 
  
6.11 (s, 1H, ArCH). 13C NMR (CD3OD) δu 132.0, 130.5, 130.0, 129.3, 128.9, 127.3, 126.0, 87.0; 
δd 139.8, 136.5, 122.5. Anal. calcd. for C13H13ClBrNO C=49.63, H=4.17, N=4.45.Found: 
C=49.63%, H =4.48%, N =4.38%. 
O-(3,5-Dichloro-α-phenylbenzyl)hydroxylamine hydrochloride (2).  Synthesized from 3,5-
dichloro-α-phenyl-benzenemethanolaccording to the general procedure to afford 2 as white 
crystals in 88%yield. Mp= 172-177 oC. 1H NMR (CD3OD) δ 7.38-7.44 (m, 4H, ArH), 7.24(d, 2H, 
ArH, J=8.6 Hz), 6.84-6.87 (d, 2H, ArH, J=6.68 Hz), 6.01 (s, 1H, ArCH). 13C NMR (CD3OD) δu 
131.7, 131.2, 130.9, 129.5, 127.8, 88.5; δd 143.6, 138.4, 137.6. Anal. calcd. for C13H12Cl3NO: 
C=51.26; H=3.97; N=4.60. Found: C=51.54%, H = 3.69%, N =4.57%.  
O-(3,4-Dichlorophenylbenzyl)hydroxylamine hydrochloride (3). Synthesized from respective 
alcohol according to the general procedure to afford 3 as white crystals in 67% yield. Mp=155-
156oC.1H NMR (CD3OD) δ 7.61 (d, 2H, ArH, J=8.0Hz),δ 7.50-7.44 (m, 4H, ArH),δ 7.36-7.34 (d, 
1H, ArH, J=8.0Hz), δ 6.18 (s, 1H, ArCH(ONH2)). 13C NMR (CD3OD) δu 130.8, 129.4, 129.1, 
129.0, 127.2, 126.9, 86.4; δd 138.0, 136.2, 132.8, 132.6. Anal. calcd. for C13H12Cl3NO:C=51.26; 
H=3.97; N=4.60, Found: C=51.26%, H = 3.65%, N =4.41%. 
O-[Bis(4-chlorophenyl)methyl]-hydroxylamine hydrochloride monohydrate (4). Synthesized 
from bis-4-chlorophenyl methanol according to the general procedure to afford 4 as white crystals 
in 49% yield. Mp=201-202oC. 1H NMR (CD3OD) δ 7.46-7.48 (d, 2H, ArH, J=8.40 Hz), 7.39-7.41 
(d, 2H, ArH, J=8.48 Hz), 6.08 (s, 1H, ArCH). 13C NMR (CD3OD) δu 128.9, 86.3; δd 135.6, 135.0. 
Anal. calcd. for C13H14Cl2NO-0.5 HCl C=48.36, H=3.91, N=4.34. Found: C=48.52%, H =3.87%, 
N =4.19%. 
5-(Aminooxy)-5-(3-chlorophenyl)-N-phenylpentanamide hydrochlorie (5). Synthesized from the 
respective alcohol according to the general procedure with the following modifications: A resin-
  
bound triphenylphosphine was used and the intermediate N-hydroxy-phthalimide intermediate 
was purified by column chromatography and then used immediately in the next hydrazinolysis 
step. The product was obtained as a white solid in 62% yield. Mp=182-184oC.  1H NMR (d6-
DMSO) δ 10.97 (br s, 3 H, NH3), 10.05 (s, 1 H, NH-C(=O)), 7.6 (d, 1 H, ArH, J=8.0 Hz), 7.47 (d, 
3 H, ArH, J=4.0 Hz), 7.39-7.37 (m, 1 H, ArH), 7.27 (t, 2 H, ArH, J=8.0 Hz), 7.01 (t, 1 H, ArH, 
J=8.0 Hz), 5.19 (t, 1 H, NO-CH, J=6.4 Hz), 2.37 (t, 2 H, O=CCH2, J=4.0 Hz), 1.97-1.88 (m, 1 H, 
CH2), 1.78-1.60 (m, 2 H, CH2), 1.58-1.47 (m, 1 H, CH2). 
13C NMR (d6-DMSO) δu 131.1, 129.3, 
129.1, 127.6, 126.4, 123.4, 119.5, 85.0; δd 171.3, 141.0, 139.8, 133.8, 36.1, 34.8, 21.6. GC tR = 
22.528 min. 
O-(2,4-Dichlorophenylbenzyl)hydroxylamine hydrochloride (6). Synthesized from 2,4-
dichlorophenylbenzhydrol according to the general procedure to afford 6 as white crystals in 76% 
yield. Mp=170-171.5oC. 1H NMR (CD3OD) δ 7.56-7.57 (m, 2H, ArH),7.47-7.51 (m, 6H, ArH)  
6.46 (s, 1H, ArCH). 13C NMR (CD3OD) δu 129.6, 128.9, 128.8, 127.8, 127.7, 84.0; δd 135.4, 135.0, 
134.0, 133.7. Anal. calcd. for C13H12Cl3NO-0.25 HCl: C=49.77, H=3.94, N=4.47. Found: 
C=49.66%, H =4.17%, N =4.40%.  
O-(3,5-Diflouro-α-phenylbenzyl)hydroxylamine hydrochloride (7). Synthesized from 3,5-
diflouro-α-phenyl benzenemethanol according to the general procedure to afford 7 as white 
crystals in 89% yield. Mp=177-181oC.1H NMR (CD3OD) δ 7.65-7.68 (m, 3H, ArH) 7.45-7.48 (m, 
1H, ArH),7.36-7.44 (m, 4H, ArH), 6.52 (s, 1H, ArCH). 13C NMR (CD3OD) δu 129.5, 128.9, 127.3, 
110.0 (q, 2JC-F=19, 8 Hz), 103.9 (t, 
2JC-F=25 Hz) 86.4; δd 163.3 (dd, 1JC-F=250 Hz, 3JC-F=13 Hz), 
141.7 (d, JC-F=8 Hz), 136.1. GC tR = 10.764 min.  
O-(4-Chloro-α-phenylbenzyl)hydroxylamine hydrochloride (8). Synthesized from 4-chloro-α-
phenyl-benzenemethanol according to the general procedure to afford 8 as white crystals in 54% 
  
yield. Mp-171-175oC.1H NMR (CD3OD) δ 7.38-7.44 (m, 4H, ArH), 7.24 (d, 2H, ArH, J=8.6 Hz), 
6.85 (t, 1H, ArH, J=6.7 Hz), 6.01 (s, 1H, ArCH2). 
13C NMR (CD3OD) δu 129.2, 128.8, 128.4, 
127.2, 87.2; δd 136.6, 136.0, 134.9. Anal. calcd. for C13H13Cl2NO: C=57.80; H=4.85; N=5.18. 
Found: C=58.02%, H = 4.58%, N =5.14%. 
O-(3-Flouro-α-phenylbenzyl)hydroxylamine hydrochloride (9). Synthesized from 3-flouro-α-
phenyl-benzenemethanol according to the general procedure to afford 9 as white crystals in 77% 
yield. Mp=169-170oC.1H NMR (CD3OD) δ 7.43-7.44 (m, 6H, ArH) 7.24-7.26 (m, 1H, ArH),7.14-
7.20 (m, 2H, ArH), 6.15 (s, 1H, ArCH). 13C NMR (CD3OD) δu 130.6 (d, 3JC-F=8 Hz), 129.2, 128.8,  
127.3, 123.0 (d, 3JC-F=3 Hz), 115.6 (d, 
2JC-F=21 Hz), 113.8 (d, 
2JC-F=23 Hz), 87.0; δd 163.0 (d, 1JC-
F=245 Hz), 139.9 (d, 
3JC-F=7 Hz), 136.6. Anal. calcd. for C13H13ClFNO C=61.55; H=5.17; N=5.52. 
Found: C=61.21%, H = 4.79%, N =5.48%. 
O-(2-Fluoro-3-trifluoromethyl-α-phenylbenzyl)hydroxylamine hydrochloride (10). Synthesized 
from 2-fluoro-4-trifluoromethyl)-α-phenyl benzenemethanol according to the general procedure 
to afford 10 as white crystals in 61% yield. Mp=157-158oC. 1H NMR (CD3OD) δ 7.38-7.44 (m, 
4H, ArH), 7.24 (d, 2H, ArH, J=8.6), 6.85 (t, 1H, ArH, J=6.7), 6.01 (s,1H, ArCH(ONH2)). 
13C NMR 
(CD3OD) δu 132.1 (d, 3JC-F=3 Hz), 129.6, 129.0, 127.9 (m), 127.2, 124.9 (d, 3JC-F=5 Hz), 81.1 (d, 
3JC-F=3 Hz); δd 157.2 (d, 1JC-F=250 Hz), 135.2, 126.7 (t, 2JC-F=13 Hz), 122.5 (d, 1JC-F=270 Hz), 
118.4 (q, 2JC-F=33, 12 Hz). Anal. calcd. for C14H12ClF4NO: C=52.27, H=3.76, N=4.35. Found: 
C=52.39%, H =3.49%, N =4.29%. 
O-(3-(3-chlorophenyl)-1-phenylpropyl)hydroxylamine hydrochloride (11) Synthesized from the 
respective alcohol according to the general procedure to afford 11. Mp=140.5-141.5oC.  1H NMR 
(CD3OD) δ 7.44-7.54 (m, 5 H, ArH), 7.28 (t, 1 H, ArH, J=8.0 Hz), 7.22 (s, 2 H, ArH), 7.13 (d, 1 
H, ArH, J=8.0 Hz), 4.98 (t, 1 H, ArCH(ONH2), J=6.9 Hz), 2.59-2.76 (m, 2 H, ArCH2), 2.27-2.37 
  
(m, 1 H, ArCH2CH2), 2.05-2.15 (m, 1 H, ArCH2CH2). 
13C NMR (CD3OD) δu 129.7, 129.6, 129.0, 
128.1, 127.2, 126.5, 126.0, 86.5; δd 143.0, 136.6, 134.0, 36.6, 30.8. GC tR =14.656 min. 
O-(2,4-Difluorophenylbenzyl)hydroxylamine hydrochloride (12). Synthesized from respective 
alcohol according to the general procedure to afford 12 as white crystals in 62% yield. Mp=167-
168oC. 1H NMR (CD3OD) δ 7.46-7.43 (overlapping signal, 5H, ArH), δ 7.11-7.05 (overlapping 
signal, 2H, ArH), δ 6.38 (s, 2H, ArCH(ONH2)). 13C NMR (CD3OD) δu 129.6 (d, 3JC-F=4 Hz), 129.5 
(d, 3JC-F=4 Hz), 129.3, 128.8, 127.1, 111.7 (q, 
2JC-F=22 Hz,
 3JC-F=4 Hz), 104.0 (t, 
2JC-F=25 Hz), 81.4 
(d, 3JC-F=3 Hz); δd 163.6 (d, 1JC-F=249 Hz, 3JC-F=13 Hz), 160.8 (d, 1JC-F=249 Hz, 3JC-F=12 Hz), 
135.6, 120.9 (q, 2JC-F=13 Hz, 
4JC-F=4 Hz). GC tR = 10.835 min.  
O-((2-Fluoro-5-trifluoromethyl-α-phenylbenzyl)hydroxylamine hydrochloride (13). 
Synthesized from the respective alcohol according to the general procedure to afford 13 as white 
crystals in 91% yield. Mp=157-158.5oC. 1H NMR (CD3OD) δ 7.78-7.82 (m, 2H, ArH ), 7.40-
7.51(m, 6H, ArH),6.45(1H, ArCH(ONH2)). 
13C NMR (CD3OD) δu 129.6, 129.0, 128.5, 127.3, 
125.0 (t, 3JC-F=4 Hz), 116.9 (d, 
2JC-F=23 Hz), 81.3; δd 162.1 (d, 1JC-F=254 Hz), 135.1, 129.6, 126.3 
(d, 2JC-F=14 Hz). GC tR = 10.494 min.  
O-(2,3-Dichloro-α-phenylbenzyl)hydroxylamine hydrochloride (14). Synthesized from 2,3-
dichloro-α-phenyl-benzenemethanol according to the general procedure to afford 14 as white 
crystals in 63%yield. Mp=170-175oC. 1H NMR (CD3OD) δ 7.64 (dd, 1H, ArH,  J=2.1, 8.0 Hz), 
7.60 (dd, 1H, ArH, J=1.4 Hz, 7.8 Hz), 7.42-7.80 (m, 6H, ArH), 6.53 (s,1H, ArCH). 13C NMR 
(CD3OD) δu 130.8, 129.5, 128.8, 128.2, 128.0, 125.9, 84.8; δd 137.2, 135.0, 133.6, 131.1. Anal. 
calcd. for C13H12Cl3NO: C=51.26; H=3.97; N=4.60. Found: C=51.27%, H = 3.90%, N =4.52%. 
O-[Bis(4-fluorophenyl)methyl]-hydroxylamine hydrochloride (15). Synthesized from bis-4-
fluorophenyl methanol according to the general procedure to afford 15 as white crystals in 58% 
  
yield. Mp=164-165.5oC. 1H NMR (CD3OD) δ 7.44-7.46  (m, 4H, ArH), 7.18-7.23 (m, 4H, ArH), 
6.12 (s,1H, ArCH). 13C NMR (CD3OD) δu 129.5 (d, 3JC-F=8 Hz), 115.5 (d, 2JC-F=22 Hz), 86.4; δd 
163.2 (d, 1JC-F=246 Hz), 133.0 (d, 
4JC-F=3 Hz). Anal. calcd. for C13H12ClF2NO C=57.47, H=4.45; 
N=5.16. Found: C=57.29%, H = 4.51%, N =5.16%. 
O-(2-Fluoro-α-phenylbenzyl)hydroxylamine hydrochloride (16). Synthesized from 2-fluoro-α-
phenyl benzenemethanol according to the general procedure to afford 16 as white crystals in 
85%yield. Mp=184-185oC. 1H NMR (CD3OD) δ 7.42-7.50 (m, 7H, ArH), 7.27-7.31 (t, 1H, ArH, 
J=6.60 Hz), 7.18-7.23 (t, 1H, ArH, J=8.64 Hz), 6.44 (s, 1H, ArCH). 13C NMR (CD3OD) δu 131.0 
(d, 3JC-F=8 Hz), 129.2, 128.8, 127.8 (d, 
4JC-F=3 Hz), 127.2, 124.6 (d, 
3JC-F=4 Hz), 115.6 (d, 
2JC-F=22 
Hz), 81.8 (d, 3JC-F=4 Hz); δd 160.4 (d, 1JC-F=246 Hz), 135.9, 124.5 (d, 2JC-F=13 Hz). Anal. Calcd. 
for C13H13ClFNO C=61.83; H=5.17; N=5.52. Found: C=61.83%, H = 4.89%, N =5.48%. 
O-(1,3-diphenylpropyl)hydroxylamine hydrochloride (17). Synthesized from 1,3-
diphenylpropan-1-ol according to the general procedure to afford 17 in 40% yield. Mp=156-159oC. 
1H NMR (CD3OD) δ 7.45-7.54 (m, 5 H, ArH), 7.30 (t, 2 H, ArH, J=7.9 Hz), 7.20 (t, 2 H, ArH, 
J=6.2 Hz), 4.97 (t, 1 H, ArCH(ONH2), J=6.9 Hz), 2.60-2.74 (m, 2 H, ArCH2), 2.28-2.37 (m, 1 H, 
ArCH2CH2), 2.05-2.14 (m, 1 H, ArCH2CH2). 
13C NMR (CD3OD) δu 129.5, 129.0, 128.2, 128.0, 
127.2, 126.8, 125.9, 86.9; δd 140.5, 136.8, 37.0, 31.1. GC tR = 12.784 min. 
O-(2-Bromo-α-phenylbenzyl)hydroxylamine hydrochloride (18). Synthesized from 2-bromo-α-
phenyl-benzenemethanol according to the general procedure to afford 18 as white crystals in 34% 
yield. Mp=166-167oC. 1H NMR (CD3OD) δ 7.71 (dd, 1H, ArH, J=8.0, 1.6 Hz) 7.61 (dd, 1H, ArH, 
J=8.0, 1.6 Hz), 77.53 (dt, 1H, ArH, J=8.0, 1.6 Hz), 7.40-7.48 (m, 5H, ArH), 7.36 (dt, 1H, J=8.0, 
1.6 Hz), 6.47 (s, 1H, ArCH). 13C NMR (CD3OD) δu 135.4, 130.6, 129.3, 129.0, 128.7, 128.0, 
  
127.9, 127.2, 86.6; δd 136.2, 135.4, 123.1. Anal. calcd. for C13H13ClBrNO: C=49.63; H=4.17; 
N=4.45. Found: C=49.78%, H =4.38%, N =4.63%. 
O-(2-Chloro-α-phenylbenzyl)-hydroxylamine hydrochloride (19). Synthesized from 3-chloro-α-
phenyl-benzenepropanol according to the general procedure to afford 19 as white crystals in 
84%yield. Mp=169-174oC.1H NMR (CD3OD) δ 7.50 (d, 1H, ArH, J=4.0 Hz), 7.41-7.48 (m, 8H, 
ArH), 6.51 (s, 1H, ArCH). 13C NMR (CD3OD) δu 130.3, 129.9, 129.3, 128.9, 128.7, 127.9, 127.6, 
127.5, 84.5; δd 135.5, 134.7, 133.2. GC tR = 13.022 min.  
O-(2-Methoxy-α-phenylbenzyl)hydroxylamine hydrochloride (20). Synthesized from 2-
methoxy-α-phenyl-benzenemethanol according to the general procedure to afford 20 as white 
crystals in 89%yield. Mp=134-134.5oC. 1H NMR (CD3OD) δ 7.35-7.46 (m, 6H, ArH), 6.98-7.01 
(m, 3H, ArH), 6.08 (s, 1H, ArCH), 3.81 (s, 3H, ArOCH3). 
13C NMR (CD3OD) δu 129.9, 129.0, 
128.6, 127.2, 119.3, 114.2, 112.9, 87.8, 54.4; δd 160.2, 138.4, 137.0. Anal. calcd. for C14H16ClNO2: 
C=63.28, H=6.07, N=5.27. Found: C=63.44%, H = 6.23%, N =5.31%. 
O-(phenyl(thiophen-3-yl)methyl)hydroxylamine hydrochloride (21).  Synthesized from 2-
methoxy-α-phenyl-benzenemethanol according to the general procedure to afford 21 as white 
crystals in 61% yield. Mp=138-139.5oC. 1H NMR (CD3OD) δ 7.41-7.53 (m, 7 H, ArH), 7.14 (dd, 
1 H, ArH, J=5.0, 1.0 Hz), 6.27 (s, 1 H, ArCH(ONH2)). 
13C NMR (CD3OD) δu 129.3, 128.7, 128.6, 
127.2, 127.0, 126.1, 125.2, 84.2; δd 138.1, 136.8. GC tR =10.857 min. 
O-(cyclohexyl(phenyl)methyl)hydroxylamine hydrochloride (22). Synthesized from 
cyclohexyl(phenyl)methanol according to the general procedure to afford 22 in 87% yield. 
Mp=193-196.5oC. 1H NMR (CD3OD) δ 7.38-7.52 (m, 5 H, ArH), 4.70 (d, 1 H, ArCH(ONH2), 
J=8.2 Hz), 2.14 (d, 1 H, CHCHONH2, J=6.4 Hz), 1.76-1.85 (m, 2 H, CH2), 1.65-1.68 (m, 2 H, 
  
CH2), 1.12-1.37 (m, 5 H, CH2), 0.9-1.03 (m, 1 H, CH2). 
13C NMR (CD3OD) δu 129.3, 128.8, 127.6, 
91.7, 42.7 δd 135.9, 29.2, 28.5, 25,8, 25.4, 25.2. GC tR =10.232 min. 
O-[4-Chloro-α-(2’-methyl,4’-methoxyphenyl)benzenemethyl]hydroxylamine hydrochloride 
(23). Synthesized from the respective alcohol according to the general procedure to afford 23 as 
white crystals in 72% yield. Mp=139.5-140.5oC. 1H NMR (CD3OD) δ 7.36-7.43 (m, 4H, ArH), 
7.19-7.21 (d, 1H, ArH J=7.76 Hz), 6.88-6.93 (m, 2H, ArH), 6.43(s, 1H, ArCHONH2), 3.87 (s, 3H, 
ArOCH3), 2.39 (s, 3H, ArCH3). 
13C NMR (CD3OD) δu 129.2, 128.5, 126.7, 121.3, 111.8, 81.6, 
54.7, 20.3; δd 157.3, 141.2, 136.0, 134.4, 121.6. Anal. calcd. for C15H17Cl2NO2: C=57.34, H=5.45, 
N=4.46. Found: C=57.60%, H = 5.52%, N =4.36%. 
O-(3,5-Bis-trifluoromethyl-α-phenyl-benzyl)hydroxylamine hydrochloride (24). Synthesized 
from 3,5-bis-trifluoromethyl-α-phenyl benzenemethanol according to the general procedure to 
afford 24 as white crystals in 88%yield. Mp=158-160oC.1H NMR (CD3OD) δ  7.90 (m, 3H, ArH), 
7.38-7.56 (m, 5H, ArH), 6.31(s, 1H, ArCH). 13C NMR (CD3OD) δu 129.8, 129.2,  127.5, 122.5 
(m), 86.0; δd 141.0, 135.7, 132.0 (q, 2JC-F=33 Hz), 123.2 (q, 1JC-F=270 Hz). Anal. calcd. for 
C15H12ClF6NO: C= 48.47, H=3.25, 3.77. Found: C=48.90%, H =2.98%, N =3.76%. 
O-(4-Hydroxy-α-phenyl)-benzyl hydroxylamine hydrochloride.(25) Synthesized from the 4-
[[(1,1-dimethylethyl)dimethylsilyl]oxy]-α-phenyl-benzenemethanol (25s) according to the 
general procedure to afford  O-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-α-phenyl-
benzyl]hydroxylamine. To a solution of the protected phenol (0.3-3.5mmol) in anhydrous 
tetrahydrofuran (5-25 mL) was added tetrabutylammonium fluoride (1 M, 1.0 equiv per TBDMS), 
and the pale yellow solution was stirred for 45 min. The mixture was poured into water and 
extracted with ethyl acetate. Removal of the solvent in vacuo from the organic phase afforded a 
tan oil that was subjected to gravity column chromatography (9:1 hexane/ethyl acetate). Formation 
  
of the HCl salt followed the general procedure to afford 25 as white crystals in 57% yield. 
Mp=168.5-169.5oC.  1H NMR (CD3OD) δ 7.38-7.46 (m, 5H, ArH), 7.24 (d, 2H, ArH, J=8.6 Hz), 
6.86 (d, 2H, ArH, J=8.6 Hz), 6.01 (s, 1H, ArCH). ). 13C NMR (CD3OD) δu 129.8, 128.8, 127.7, 
115.6, 69.1; δd 158.5, 134.1, 123.9. Anal. calcd. for C13H14ClNO2-H2O: C=57.89; H=5.98; N=5.19. 
Found: C=58.03% H=6.01% N= 5.20% .  
O-(3-Trifluoromethyl-α-phenylbenzyl)hydroxylamine hydrochloride (26). Synthesized from 
phenyl(3-(trifluoromethyl)phenyl)methanol according to the general procedure to afford 26 as 
white crystals in 77%yield. Mp=199-199.5oC. 1H NMR (CD3OD) δ 7.61 (d, 1H, ArH, J=2.3 Hz), 
7.58 (s, 1H, ArH), 7.50 (dd, 1H, ArH, J=8.6, 2.2 Hz), 6.47 (s, 1H, ArCH). ). 13C NMR (CD3OD) 
δu 132.8, 129.6, 129.3, 128.8, 128.7, 127.6, 126.2 (q, 3JC-F=6 Hz), 83.4; δd 136.1, 135.0, 128.3 (d, 
2JC-F=30 Hz), 124.2 (q, 
1JC-F=272 Hz). Anal. calcd. for C14H13ClF3NO: C=55.37; H=4.31; N=4.61. 
Found: C=55.52%, H = 4.58%, N =5.04%.  
 
Enzyme-based IDO1, IDO2 and TDO inhibition assays. The steady-state activity of each 
enzyme was measured in the absence or presence of an inhibitor at 20 ℃ with a protocol reported 
previously48, 49 (with small modifications).  For IDO1, each reaction was initiated by mixing 50 
µM L-tryptophan with 100 nM enzyme in 50 mM Tris buffer (pH 7.4) that contained 200 nM 
catalase, 12 µM methylene blue, 20 mM ascorbate and 100 M inhibitor (unless otherwise 
indicated). The same protocol was used for IDO2 except that 4 mM L-tryptophan and 1 µM 
enzyme were used; in addition pyocyanin (39 µM) instead of methylene blue was used as an 
electron mediator. For TDO, the experiment was initiated by mixing 100 µM L-tryptophan with 
250 nM enzyme in 50 mM Tris buffer (pH 7.4) that contained 100 µM ascorbate and 100 M 
inhibitor (unless otherwise indicated). The inhibitor stocks were prepared in dimethyl sulfoxide 
  
(DMSO), the final DMSO concentration for all reactions was kept at 3.5% (v/v). The initial linear 
velocities of the reactions, v, were obtained by monitoring the formation of the product N-formyl 
kynurenine at 321 nm ( = 3750 M-1cm-1) as a function of time with a UV2400 spectrophotometer 
(Shimadzu Scientific Instruments, Inc.) with a spectral slit width of 2 nm.  The % inhibition for 
each inhibitor was calculated based on (1-v/vo )x100, where vo was obtained in the absence of any 
inhibitor. For each inhibitor that exhibited ≥95% inhibition activity for IDO1 or TDO, or ≥85% 
inhibition activity for IDO2, the IC50 value was determined by measuring the inhibition activity as 
a function of inhibitor concentration. It is noted that the threshold for IDO2 was set lower (85%) 
for the initial screening due to the generally lower inhibition activity of the inhibitors. All the data 
were analyzed with Origin 6.1 software (Microcal Software, Inc., MA). 
 
Cell-based IDO1, IDO2 and TDO inhibition assays. Compounds were evaluated for inhibitory 
activity against human IDO1 expressed endogenously in HeLa cells and human TDO and mouse 
IDO2 expressed exogenously in T-Rex cells. HeLa cells were seeded in a 96 well plate at a 
density of 10,000 cells per well in 100 μl DMEM + 10% fetal bovine serum + 1% penicillin-
streptomycin with L-tryptophan being  adjusted to 100 μM and IDO1 expression was induced by 
the addition of IFNγ to a final concentration of 100 ng/mL. T-Rex cells containing a tet-regulated 
human TDO were seeded in a 96-well plate at a density of 10,000 cells per well in 100 μL of 
DMEM + 10% FBS + 1% penicillin-streptomycin with L-tryptophan adjusted to 100 μM and 
TDO expression was induced by the addition of 100 μL of media containing  2 ng/mL 
doxycycline  with adjusted L-tryptophan. T-Rex cells containing a tet-regulated mouse IDO2 
cDNA were seeded in a 96-well plate at a density of 10,000 cells per well in 100 μL of DMEM + 
10% FBS + 1% penicillin-streptomycin and IDO2 expression was induced by the addition of 100 
  
μL of media containing 2 ng/mL doxycycline + 8 mM 5-aminolevulinic acid + 20 μM hemin + 4 
mM L-tryptophan.  The IDO1 and TDO induction was allowed to proceed for 24 hours, the 
IDO2 was induced for 48 hours. After induction, the media was discarded, the wells rinsed once, 
and serial dilutions of compound in 200 μL of appropriate media with the final concentration of 
tryptophan adjusted to 100 μM for IDO1 and TDO and to 2mM for IDO2. Following incubation 
at 37 °C for an additional 20 hrs, the assay was stopped by the addition of 50 μL of 50% (w/v) 
TCA to each well, and the cells were fixed by incubating for 1 hr at 4 °C. 
Assessment of IDO1, IDO2 and TDO activity  
Compound IC50 values were assessed from single point dilution series with the most potent 
compounds subsequently retested two or more times and the results reported as averages. 
Following the TCA fixation step, the supernatants were transferred to a round-bottomed 96-well 
plate and incubated at 65 °C for 15 min. The plates were then centrifuged at 1250 × g for 10 min, 
and 100 μL of clarified supernatant was transferred to a new flat-bottomed 96-well plate and 
mixed at equal volume with 2% (w/v) p-dimethylaminobenzaldehyde in acetic acid. The yellow 
reaction was measured at 490 nm using a Synergy HT microtiter plate reader (Bio-Tek, 
Winooski, VT). Graphs of inhibition curves with IC50 values were generated using Prism v.5.0 
(GraphPad Software, Inc.). 
 
Supplementary Data  
Full experimental details for the synthesis of alcohols that were not commercially available are 
described. Copies of 1H and 13C NMR spectra for all tested hydroxylamine compounds are also 
available. Raw IC50 data for top inhibitors in the enzyme and cell-based inhibition assays are 
  
shown. Toxicity screen with HeLa cells for diaryl hydroxylamines, epacadostat and PF-0684003 
are available. In addition, an assay assessing the impact of human serum protein binding on the 
apparent IC50 values is also shown. This material is available at … 
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